Capital Advisors Ltd’s Cytokinetics CYTK Stock Holding History

Capital Advisors Ltd’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14K	Hold	164	–	–	﹤0.01%	769
2026 Q1	$11K	Hold	164	–	–	﹤0.01%	801
2025 Q4	$10K	Hold	164	–	–	﹤0.01%	805
2025 Q3	$9K	Hold	164	–	–	﹤0.01%	818
2025 Q2	$5K	Sell	164 -6	-4%	-$209	﹤0.01%	921
2025 Q1	$7K	Hold	170	–	–	﹤0.01%	846
2024 Q4	$8K	Hold	170	–	–	﹤0.01%	828
2024 Q3	$9K	Hold	170	–	–	﹤0.01%	790
2024 Q2	$9K	Hold	170	–	–	﹤0.01%	767
2024 Q1	$12K	Hold	170	–	–	﹤0.01%	678
2023 Q4	$14K	Buy	170 +20	+13%	+$724	﹤0.01%	622
2023 Q3	$4K	Hold	150	–	–	﹤0.01%	868
2023 Q2	$5K	Buy	+150	New	+$5.55K	﹤0.01%	827
2023 Q1	–	Sell	-150	Closed	–	–	1265
2022 Q4	$0	Buy	+150	New	+$6.45K	﹤0.01%	1299

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Advisors Ltd's CYTK Position: Q2 2026 in Review

Capital Advisors Ltd held its Cytokinetics (CYTK) position steady in Q2 2026 at 164 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #769.

Capital Advisors Ltd first reported a position in CYTK in Q4 2022 and has held it in 14 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Capital Advisors Ltd held 164 shares of Cytokinetics worth $14K as of Q2 2026.
Capital Advisors Ltd left its Cytokinetics share count unchanged in Q2 2026.
Cytokinetics made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q2 2026, its #769 holding.
Capital Advisors Ltd first reported a position in Cytokinetics in Q4 2022 and has held it in 14 quarters since.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.